Cohance Lifesciences

COHANCE

NSE

BSE

SectorHealthcare

Loading chart…

Company insights, generated from the most recent coverage.

Customised ADC payload delivery scheduled for Q2 FY27 — near-term catalyst driving speculative buying as investors position ahead of the milestone.
Stock up 3.06% to ₹469.9 on September 1, 2026 — driven by ADC sector buzz, upcoming Q2 delivery milestone, and broader CRDMO tailwinds despite low volume (-57% vs 1-month avg).
Financial Express feature comparing Cohance with Piramal Pharma and Anthem Biosciences as top Indian CDMO plays in ~$20B ADC market — fresh media spotlight driving investor interest.

About the company

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.

Company insights, generated from the most recent coverage.

Customised ADC payload delivery scheduled for Q2 FY27 — near-term catalyst driving speculative buying as investors position ahead of the milestone.
Stock up 3.06% to ₹469.9 on September 1, 2026 — driven by ADC sector buzz, upcoming Q2 delivery milestone, and broader CRDMO tailwinds despite low volume (-57% vs 1-month avg).
Financial Express feature comparing Cohance with Piramal Pharma and Anthem Biosciences as top Indian CDMO plays in ~$20B ADC market — fresh media spotlight driving investor interest.

Cohance Lifesciences

Insights

About the company

Insights